Axsome Therapeutics Inc [AXSM] stock is trading at $100.49, up 1.42%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The AXSM shares have gain 3.07% over the last week, with a monthly amount glided 13.11%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Axsome Therapeutics Inc [NASDAQ: AXSM] stock has seen the most recent analyst activity on September 03, 2024, when Wells Fargo initiated its Overweight rating and assigned the stock a price target of $140. Previously, BofA Securities upgraded its rating to Buy on August 06, 2024, and elevated its price target to $106. On July 22, 2024, Needham initiated with a Buy rating and assigned a price target of $130 on the stock. Morgan Stanley upgraded its rating to a Overweight and increased its price target to $115 on April 29, 2024. Robert W. Baird initiated its recommendation with a Outperform and recommended $108 as its price target on March 19, 2024. UBS started tracking with a Buy rating for this stock on February 06, 2024, and assigned it a price target of $111. In a note dated January 25, 2024, RBC Capital Mkts initiated an Outperform rating and provided a target price of $126 on this stock.
Axsome Therapeutics Inc [AXSM] stock has fluctuated between $64.11 and $105.00 over the past year. Currently, Wall Street analysts expect the stock to reach $122.42 within the next 12 months. Axsome Therapeutics Inc [NASDAQ: AXSM] shares were valued at $100.49 at the most recent close of the market. An investor can expect a potential return of 21.82% based on the average AXSM price forecast.
Analyzing the AXSM fundamentals
Axsome Therapeutics Inc [NASDAQ:AXSM] reported sales of 338.46M for the trailing twelve months, which represents a growth of 81.27%. Gross Profit Margin for this corporation currently stands at 0.91% with Operating Profit Margin at -0.91%, Pretax Profit Margin comes in at -0.92%, and Net Profit Margin reading is -0.92%. To continue investigating profitability, this company’s Return on Assets is posted at -0.55, Equity is -2.34 and Total Capital is -0.84. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.94.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 98.99 points at the first support level, and at 97.50 for the second support level. However, for the 1st resistance point, the stock is sitting at 101.99, and for the 2nd resistance point, it is at 103.50.
Ratios To Look Out For
For context, Axsome Therapeutics Inc’s Current Ratio is 2.44. In addition, the Quick Ratio stands at 2.37 and the Cash Ratio stands at 1.67. Considering the valuation of this stock, the price to sales ratio is 14.39, the price to book ratio is 52.39.
Transactions by insiders
Recent insider trading involved Saad Mark E, Director, that happened on Sep 11 ’24 when 11016.0 shares were sold. Director, Saad Mark E completed a deal on Sep 11 ’24 to buy 11016.0 shares. Meanwhile, Chief Operating Officer Jacobson Mark L. sold 47739.0 shares on Aug 09 ’24.
